Skip to main content
Terug
Watch Compare

Telomir Pharmaceuticals, Inc.

Datakwaliteit: 83%
TELO
NASDAQ Manufacturing Chemicals
€ 1,31
▲ € 0,01 (0,77%)
6 months return
—
Momentum
Neutral
ROE
-279,15%

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-279,15%
Onder sectorgemiddelde (-54,68%)
ROICN/A
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio17,51
Interest CoverageN/A

Waardering

PE (TTM)
-4,19
Onder sectorgemiddelde (-1,50)
P/B Ratio6,26
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -3,69 M

Price History

Financiële Trends

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstverassingen

EPS
Reported Estimate
Q42024 Q12025 Q22025 Q32025
Reported -€ 0,10 -€ 0,07 -€ 0,17 -€ 0,03
Estimate -€ 0,05 -€ 0,10 -€ 0,08 -€ 0,07
Verrassing -100,00% +30,00% -112,50% +57,14%

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -279,15% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -10,41 M
ROE -279,15% ROA -253,00%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -3,69 M
ROIC N/A FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 17,51
Debt / Equity N/A Current Ratio 17,51
Interest Coverage N/A Asset Turnover N/A
Working Capital 6,98 M Tangible Book Value 6,98 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -4,19 · EV/EBITDA: N/A
P/E Ratio -4,19 Forward P/E N/A
P/B Ratio 6,26 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -8,45%
Market Cap 43,66 M Enterprise Value 43,66 M

Per Share

EPS: -0,33 · FCF/Share: -0,11
EPS (Diluted TTM) -0,33 Revenue / Share N/A
FCF / Share -0,11 OCF / Share -0,11
EPS CAGR (1Y) -158,93% EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 35,42% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 35,42%
SBC-Adj. FCF -8,99 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023
Revenue — — —
Net Income -10,41 M -16,53 M -13,07 M
EPS (Diluted) -0,33 0,56 -0,45
Gross Profit — — —
Operating Income — — —
EBITDA — — —
R&D Expenses 2,44 M 2,24 M 1,57 M
SG&A Expenses — — —
D&A — — —
Interest Expense 4,34 M 4,34 M 1,64 M
Income Tax — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023
Total Assets 7,34 M 1,32 M 4,77 M
Total Liabilities 1,43 M 680.968,0 1,34 M
Shareholders' Equity 5,91 M 643.037,0 3,44 M
Total Debt — — —
Cash & Equivalents — — —
Current Assets 7,34 M 1,32 M 435.225,0
Current Liabilities 1,43 M 680.968,0 1,34 M

Sectorvergelijking

vs Manufacturing sector mediaan (1605 peers)
Metriek Aandeel Sector Mediaan
P/E -4,2 -1,5
P/B 6,3 1,6
ROE % -279,2 -54,7
Net Margin % — -41,5
Rev Growth 5Y % — 1,7
D/E — 0,3